Adjuvant Therapy for Node-Negative Breast Cancer

K. C. Lee; Clyde B. Schechter; Melody A. Cobleigh; Stuart M. Lichtman; Daniel R. Budman; John H. Donohue; David M. Nagorney; Clive S. Grant; Jon A. Vanheerden; Michael G. Sarr; Sylvester Sterioff; Michael B. Farnell; Donald C. Mcilrath; John H. Pemberton; Peter Mucha; Robert A. Buckman; Kathleen I. Pritchard; Donald J. Sutherland; Robert G. Mackenzie; Ida Ackerman; Mary A. Doherty; Pamela A. Catton; Ian F. Tannock; Bernard Fisher; Carol Redmond; Vincent T. Devita; Aron Goldhirsch; Richard D. Gelber; Monica Castiglione

doi:10.1056/NEJM198908173210711

Adjuvant Therapy for Node-Negative Breast Cancer

K. C. Lee
, Clyde B. Schechter
, Melody A. Cobleigh
, Stuart M. Lichtman
, Daniel R. Budman
, John H. Donohue
, David M. Nagorney
, Clive S. Grant
, Jon A. Vanheerden
, Michael G. Sarr
, Sylvester Sterioff
, Michael B. Farnell
, Donald C. Mcilrath
, John H. Pemberton
, Peter Mucha
, Robert A. Buckman
, Kathleen I. Pritchard
, Donald J. Sutherland
, Robert G. Mackenzie
, Ida Ackerman

Mary A. Doherty, Pamela A. Catton, Ian F. Tannock, Bernard Fisher, Carol Redmond, Vincent T. Devita, Aron Goldhirsch, Richard D. Gelber, Monica Castiglione

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Abstract

To the Editor: The articles on node-negative breast cancer (Feb. 23 issue)¹ ² ³ ⁴ are very important. They provide further support for treating patients with this disease. However, I am troubled by some of their conclusions. Fisher et al.^1,2 feel that all patients with node-negative cancer except those with tumors too small for estrogen-receptor analysis should be treated. This is not warranted by the data presented. First, the follow-up was only four years. Second, the benefit of treatment was seen only in disease-free survival and not in overall survival. This could mean that treatment only delays failure. Third, the treatment was not…

Original language	English (US)
Pages (from-to)	469-473
Number of pages	5
Journal	New England Journal of Medicine
Volume	321
Issue number	7
DOIs	https://doi.org/10.1056/NEJM198908173210711
State	Published - Aug 17 1989
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM198908173210711

Cite this

Lee, K. C., Schechter, C. B., Cobleigh, M. A., Lichtman, S. M., Budman, D. R., Donohue, J. H., Nagorney, D. M., Grant, C. S., Vanheerden, J. A., Sarr, M. G., Sterioff, S., Farnell, M. B., Mcilrath, D. C., Pemberton, J. H., Mucha, P., Buckman, R. A., Pritchard, K. I., Sutherland, D. J., Mackenzie, R. G., ... Castiglione, M. (1989). Adjuvant Therapy for Node-Negative Breast Cancer. New England Journal of Medicine, 321(7), 469-473. https://doi.org/10.1056/NEJM198908173210711

Lee, KC, Schechter, CB, Cobleigh, MA, Lichtman, SM, Budman, DR, Donohue, JH, Nagorney, DM, Grant, CS, Vanheerden, JA, Sarr, MG, Sterioff, S, Farnell, MB, Mcilrath, DC, Pemberton, JH, Mucha, P, Buckman, RA, Pritchard, KI, Sutherland, DJ, Mackenzie, RG, Ackerman, I, Doherty, MA, Catton, PA, Tannock, IF, Fisher, B, Redmond, C, Devita, VT, Goldhirsch, A, Gelber, RD & Castiglione, M 1989, 'Adjuvant Therapy for Node-Negative Breast Cancer', New England Journal of Medicine, vol. 321, no. 7, pp. 469-473. https://doi.org/10.1056/NEJM198908173210711

@article{4dfe31154ab7401589d7503a4a2443d3,

title = "Adjuvant Therapy for Node-Negative Breast Cancer",

abstract = "To the Editor: The articles on node-negative breast cancer (Feb. 23 issue)1 2 3 4 are very important. They provide further support for treating patients with this disease. However, I am troubled by some of their conclusions. Fisher et al.1,2 feel that all patients with node-negative cancer except those with tumors too small for estrogen-receptor analysis should be treated. This is not warranted by the data presented. First, the follow-up was only four years. Second, the benefit of treatment was seen only in disease-free survival and not in overall survival. This could mean that treatment only delays failure. Third, the treatment was not…",

author = "Lee, \{K. C.\} and Schechter, \{Clyde B.\} and Cobleigh, \{Melody A.\} and Lichtman, \{Stuart M.\} and Budman, \{Daniel R.\} and Donohue, \{John H.\} and Nagorney, \{David M.\} and Grant, \{Clive S.\} and Vanheerden, \{Jon A.\} and Sarr, \{Michael G.\} and Sylvester Sterioff and Farnell, \{Michael B.\} and Mcilrath, \{Donald C.\} and Pemberton, \{John H.\} and Peter Mucha and Buckman, \{Robert A.\} and Pritchard, \{Kathleen I.\} and Sutherland, \{Donald J.\} and Mackenzie, \{Robert G.\} and Ida Ackerman and Doherty, \{Mary A.\} and Catton, \{Pamela A.\} and Tannock, \{Ian F.\} and Bernard Fisher and Carol Redmond and Devita, \{Vincent T.\} and Aron Goldhirsch and Gelber, \{Richard D.\} and Monica Castiglione",

year = "1989",

month = aug,

day = "17",

doi = "10.1056/NEJM198908173210711",

language = "English (US)",

volume = "321",

pages = "469--473",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "7",

}

TY - JOUR

T1 - Adjuvant Therapy for Node-Negative Breast Cancer

AU - Lee, K. C.

AU - Schechter, Clyde B.

AU - Cobleigh, Melody A.

AU - Lichtman, Stuart M.

AU - Budman, Daniel R.

AU - Donohue, John H.

AU - Nagorney, David M.

AU - Grant, Clive S.

AU - Vanheerden, Jon A.

AU - Sarr, Michael G.

AU - Sterioff, Sylvester

AU - Farnell, Michael B.

AU - Mcilrath, Donald C.

AU - Pemberton, John H.

AU - Mucha, Peter

AU - Buckman, Robert A.

AU - Pritchard, Kathleen I.

AU - Sutherland, Donald J.

AU - Mackenzie, Robert G.

AU - Ackerman, Ida

AU - Doherty, Mary A.

AU - Catton, Pamela A.

AU - Tannock, Ian F.

AU - Fisher, Bernard

AU - Redmond, Carol

AU - Devita, Vincent T.

AU - Goldhirsch, Aron

AU - Gelber, Richard D.

AU - Castiglione, Monica

PY - 1989/8/17

Y1 - 1989/8/17

N2 - To the Editor: The articles on node-negative breast cancer (Feb. 23 issue)1 2 3 4 are very important. They provide further support for treating patients with this disease. However, I am troubled by some of their conclusions. Fisher et al.1,2 feel that all patients with node-negative cancer except those with tumors too small for estrogen-receptor analysis should be treated. This is not warranted by the data presented. First, the follow-up was only four years. Second, the benefit of treatment was seen only in disease-free survival and not in overall survival. This could mean that treatment only delays failure. Third, the treatment was not…

AB - To the Editor: The articles on node-negative breast cancer (Feb. 23 issue)1 2 3 4 are very important. They provide further support for treating patients with this disease. However, I am troubled by some of their conclusions. Fisher et al.1,2 feel that all patients with node-negative cancer except those with tumors too small for estrogen-receptor analysis should be treated. This is not warranted by the data presented. First, the follow-up was only four years. Second, the benefit of treatment was seen only in disease-free survival and not in overall survival. This could mean that treatment only delays failure. Third, the treatment was not…

UR - https://www.scopus.com/pages/publications/0024406766

UR - https://www.scopus.com/pages/publications/0024406766#tab=citedBy

U2 - 10.1056/NEJM198908173210711

DO - 10.1056/NEJM198908173210711

M3 - Letter

C2 - 2761581

AN - SCOPUS:0024406766

SN - 0028-4793

VL - 321

SP - 469

EP - 473

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 7

ER -

Adjuvant Therapy for Node-Negative Breast Cancer

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this